Kura Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
KURA$7.570.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibit and Financial Statement Schedules
- Financial Statements. We have filed the following documents as part of this Annual Report:
| Page | |
| Report of Independent Registered Public Accounting Firm | F-1 |
|---|---|
| Balance Sheets | F-3 |
| Statements of Operations and Comprehensive Loss | F-4 |
| Statements of Stockholders’ Equity | F-5 |
| Statements of Cash Flows | F-6 |
| Notes to Financial Statements | F-7 |
- Financial Statement Schedules.
There are no financial statement schedules provided because the information called for is either not required or is shown either in the financial statements or the notes thereto.
- Exhibits
| ExhibitNumber · Description · FiledHerewith · Incorporated by Reference hereinfrom Form orSchedule · Filing Date · SEC File/Reg.Number | ||||
|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant, as amended. | 8-K(Exhibit 3.1) | 6/14/2017 | 001-37620 |
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K(Exhibit 99.1) | 1/29/2026 | 001-37620 |
| 4.1 | Form of Common Stock certificate. | 8-K(Exhibit 4.1) | 3/12/2015 | 000-53058 |
| 4.2 | Form of Warrant Agreement issued by the Registrant on November 2, 2022 to certain Lenders. | 10-K(Exhibit 4.3) | 2/23/2023 | 001-37620 |
| 4.3 | Amended and Restated Warrant Agreement, dated as of November 29, 2022, by and between the Registrant and Hercules Capital, Inc. | 10-K(Exhibit 4.4) | 2/23/2023 | 001-37620 |
| 4.4 | Warrant Agreement, dated as of November 29, 2022, by and between the Registrant and Hercules Capital IV, L.P. | 10-K(Exhibit 4.5) | 2/23/2023 | 001-37620 |
| 4.5 | Description of Registrant’s Common Stock. | 10-K(Exhibit 4.3) | 2/25/2020 | 001-37620 |
| 4.6 | Form of Pre-Funded Warrant. | 8-K(Exhibit 4.1) | 1/26/2024 | 001-37620 |
| 4.7*** | Registration Rights Agreement, dated January 26, 2024, by and among the Registrant and the persons party thereto. | 8-K(Exhibit 10.2) | 1/26/2024 | 001-37620 |
| 10.1+ | Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder. | 8-K(Exhibit 99.1) | 6/6/2025 | 001-37620 |
| ExhibitNumber | Description | FiledHerewith | Incorporated by Reference hereinfrom Form orSchedule | Filing Date | SEC File/Reg.Number |
|---|---|---|---|---|---|
| 10.2+ | Form of Restricted Stock Purchase Agreement and Restricted Stock Purchase Award Notice under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan. | 8-K(Exhibit 10.2) | 3/12/2015 | 000-53058 | |
| 10.3+ | Kura Oncology, Inc. 2015 Employee Stock Purchase Plan. | 8-K(Exhibit 10.3) | 3/12/2015 | 000-53058 | |
| 10.4+ | Form of Indemnification Agreement by and between the Registrant and each of its directors and officers. | 8-K(Exhibit 10.4) | 3/12/2015 | 000-53058 | |
| 10.5* | Patent License Agreement, effective as of December 22, 2014, by and between the Registrant and the Regents of the University of Michigan, as amended on March 3, 2015, July 22, 2015, September 29, 2016, February 1, 2017. | 10-K(Exhibit 10.8) | 2/24/2021 | 001-37620 | |
| 10.6* | Fifth Amendment to Patent License Agreement, effective as of May 24, 2017, by and between the Registrant and the Regents of the University of Michigan. | 10-K(Exhibit 10.9) | 2/24/2021 | 001-37620 | |
| 10.7+ | Amended and Restated Executive Employment Agreement, effective as of January 29, 2016, by and between the Registrant and Troy E. Wilson, Ph.D., J.D. | 10-K(Exhibit 10.15) | 3/17/2016 | 001-37620 | |
| 10.8** | Sixth Amendment to Patent License Agreement, effective as of August 24, 2017, by and between the Registrant and the Regents of the University of Michigan. | 10-K(Exhibit 10.23) | 3/12/2018 | 001-37620 | |
| 10.9+ | Executive Employment Agreement, effective as of August 9, 2019, by and between the Registrant and Kathleen Ford. | 10-Q(Exhibit 10.3) | 11/5/2019 | 001-37620 | |
| 10.10 | Office Lease Agreement, dated March 24, 2020, by and between the Registrant and East Office Operating Limited Partnership. | 10-Q(Exhibit 10.5) | 5/4/2020 | 001-37620 | |
| 10.11+ | Amended and Restated Non-Employee Director Compensation Policy. | X | |||
| 10.12+ | Amendment to Amended and Restated Executive Employment Agreement, effective as of February 19, 2021, by and between the Registrant and Troy E. Wilson, Ph.D., J.D. | 10-K(Exhibit 10.36) | 2/24/2021 | 001-37620 | |
| 10.13+ | Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan. | 10-K(Exhibit 10.22) | 2/23/2023 | 001-37620 | |
| 10.14+ | Executive Employment Agreement, effective as of October 18, 2021, by and between the Registrant and Teresa Bair. | 10-K (Exhibit 10.31) | 2/24/2022 | 001-37620 | |
| 10.15 | Loan and Security Agreement dated as of November 2, 2022 by and between the Registrant, Hercules Capital, Inc. and other banks thereto. | 8-K(Exhibit 10.2) | 11/3/2022 | 001-37620 | |
| ExhibitNumber | Description | FiledHerewith | Incorporated by Reference hereinfrom Form orSchedule | Filing Date | SEC File/Reg.Number |
|---|---|---|---|---|---|
| 10.16+ | Executive Employment Agreement, effective as of August 14, 2023, by and between the Registrant and Brian Powl. | 10-Q(Exhibit 10.1) | 11/2/2023 | 001-37620 | |
| 10.17 | First Amendment to Lease, dated as of August 30, 2023, by and between the Registrant and East Office Operating Limited Partnership. | 10-Q(Exhibit 10.2) | 11/2/2023 | 001-37620 | |
| 10.18 | First Amendment to Loan and Security Agreement, dated as of October 2, 2023, by and between the Registrant, Hercules Capital, Inc. and other banks thereto. | 10-Q(Exhibit 10.3) | 11/2/2023 | 001-37620 | |
| 10.19 | Sales Agreement, dated November 2, 2023, by and among the Registrant, Leerink Partners LLC and Cantor Fitzgerald & Co. | 10-Q(Exhibit 10.4) | 11/2/2023 | 001-37620 | |
| 10.20+ | Kura Oncology, Inc. 2023 Inducement Option Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder. | 8-K(Exhibit 99.1) | 10/16/2025 | 001-37620 | |
| 10.21+ | Second Amendment to Amended and Restated Executive Employment Agreement, effective as of April 11, 2024, by and between the Registrant and Troy E. Wilson, Ph.D., J.D. | 10-Q(Exhibit 10.1) | 8/8/2024 | 001-37620 | |
| 10.22* | Collaboration and License Agreement, dated November 20, 2024, by and among the Registrant Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. | 10-K (Exhibit 10.32) | 2/28/2025 | 001-37620 | |
| 10.23+ | Third Amended & Restated Executive Employment Agreement, effective as of January 2, 2025, by and between the Registrant and Mollie Leoni, M.D. | 10-K (Exhibit 10.34) | 2/28/2025 | 001-37620 | |
| 10.24+ | Third Amended & Restated Executive Employment Agreement, effective as of January 2, 2025, by and between the Registrant and Francis Burrows, Ph.D. | 10-K (Exhibit 10.35) | 2/28/2025 | 001-37620 | |
| 10.25 | Lease, effective January 13, 2025, by and between the Registrant and HCP Life Science REIT, Inc. | 10-K (Exhibit 10.36) | 2/28/2025 | 001-37620 | |
| 10.26 | Co-Promotion and Medical Affairs Agreement, dated June 27, 2025, by and between the Registrant and Kyowa Kirin, Inc. | 10-Q (Exhibit 10.4) | 8/7/2025 | 001-37620 | |
| 10.27 | First Amendment to Lease, dated June 6, 2025, by and between the Registrant and HCP Life Science REIT, Inc. | 10-Q(Exhibit 10.2) | 8/7/2025 | 001-37620 | |
| 10.28 | Second Amendment to Loan and Security Agreement, dated as of October 25, 2025, by and among the Registrant, Hercules Capital, Inc. and other banks thereto. | 10-Q (Exhibit 10.2) | 11/4/2025 | 001-37620 | |
| 19.1 | Kura Oncology, Inc. Insider Trading Policy | 10-K (Exhibit 19.1) | 2/28/2025 | 001-37620 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | |||
| ExhibitNumber | Description | FiledHerewith | Incorporated by Reference hereinfrom Form orSchedule | Filing Date | SEC File/Reg.Number |
|---|---|---|---|---|---|
| 24.1 · Power of Attorney (see signature page). · X | |||||
| 31.1 · Certification of Principal Executive and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. · X | |||||
| 32.1 · Certification of Principal Executive and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350. · X | |||||
| 97.1 | Kura Oncology, Inc. Incentive Compensation Recoupment Policy. | 10-K(Exhibit 97.1) | 2/27/2024 | 001-37620 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | X | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS). | X | |||
- Indicates management contract or compensatory plan.
- Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K.
** Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.
*** Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.